Background: The UBA6-specific E2 conjugating enzyme 1 (USE1) ubiquitin enzyme cascade is a poorly characterized arm of the ubiquitin-proteasome system. We investigated whether the UBA6-USE1 enzyme cascade plays a role in lung cancer tumorigenesis. Methods: USE1 expression was assessed in tumor-normal paired samples from 106 lung cancer patients by immunoblot. USE1 was stably overexpressed and knocked down in lung cancer cell lines to evaluate cell proliferation, colony formation, and invasion. Xenograft models were used to determine the effects of USE1 on tumor growth (n ¼ 7). Proteomics analysis was used to identify proteins interacting with USE1. The USE1 gene was sequenced in lung cancer patients, and missense mutations of USE1 were generated to evaluate its function. All statistical tests were two-sided. Results: USE1 proteins were frequently overexpressed in lung cancer patients (92.5%) Stable overexpression of USE1 increased cell proliferation (P ¼ .002), migration (P < .001), and invasion (P < .001), whereas knockdown of USE1 reduced cell proliferation (P < .001), migration (P ¼ .003), and invasion in lung cancer cells and xenograft models (P < .001). USE1 was found to have a conserved D-box domain, and the level of the protein was regulated by the anaphase-promoting complex. Several missense mutations in USE1 identified in patients prolong the stability of the protein.
Lung cancer is the most frequent cause of cancer death, resulting in more than one million deaths worldwide. The five-year survival rate is only 15%, mainly because of late-stage detection and poor treatments. Inhibitors that target receptor tyrosine kinases or epidermal growth factor receptor have shown some efficacy, but most patients develop drug resistance (1) (2) (3) (4) (5) .
The ubiquitin-proteasome system regulates numerous signaling functions and is a major mechanism for controlling protein homeostasis and developmental decisions. In this pathway, ubiquitin is transferred to its targets via an E1-E2-E3 cascade (6, 7) . The E1 enzyme plays a fundamental role in this process, and it has been generally regarded that there is only one ubiquitin E1 enzyme. Previously, we and others identified a second E1 enzyme designated UBA6 (8) (9) (10) . UBA6-deficient mice showed embryonic lethality, whereas brain-specific UBA6-deficient mice generated in our lab displayed numerous behavioral phenotypes, confirming its crucial role in neuronal development (10) (11) (12) . UBA6-specific E2 conjugating enzyme 1 (USE1) is a member of the E2 enzyme family that contains an active cysteine residue required for the formation of a thioester bond with ubiquitin (8, 13) . Interestingly, USE1 interacts specifically with the UBA6 enzyme rather than the conventional E1 enzyme (8, 13) .
The anaphase-promoting complex/cyclosome (APC/C), a multisubunit E3 ubiquitin ligase crucial for mitotic progression, was first identified as an ubiquitin ligase for cyclin B (14, 15) . Subsequent studies showed that the APC/C is not only active at anaphase, but that its activity continues until the end of G 1 , marking a large group of cell cycle regulators for degradation (16) (17) (18) . The APC/C recognizes either a KEN box (K-E-N) or a destruction box (D-box; R-X-X-L, where X is any amino acid) in substrates (19, 20) . The D-box is recognized by either APC/C Cdc20 or APC/C Cdh1 , whereas the KEN box appears to be ubiquitylated only by APC/C Cdh1 (17, 21) .
In the present study, we unexpectedly found that USE1 is highly expressed in lung cancer patients. Thus, we employed multiple approaches to understand the molecular mechanism of the UBA6-USE1 enzyme cascade in lung cancer.
Methods
A complete description of the methods, including cell lines, primers, mass spectrometry, cell synchronization, cell viability, wound healing, invasion, soft agar, colony formation assay, and docking simulation are presented in the Supplementary Materials (available online).
Patients and Lung Tissue Samples
Experiments were performed after receiving informed consent from patients and approval from the Institutional Review Board of Asan Medical Center (2014-0960). Surgically trimmed human lung tissues were obtained through the Asan Bio Resource Center (2014-20(89)).
Mouse Studies
All mice were bred at the Animal Facilities at the Asan Institute for Life Sciences. 
Xenograft Study
Male BALB/c nude mice (4-6 weeks old) were randomly divided into experimental groups. Mice were subcutaneously injected with 2 Â 10 6 A549 cells, as indicated in the figures, in a 50 mL volume using a 27-gauge needle. After five days, the tumor size was monitored every other day. To determine tumor mass, the greatest longitudinal diameter (length) and the greatest transverse diameter (width) were measured using an external caliper every three days after injection (24) . The tumor mass was calculated by the modified ellipsoidal formula:
where V equals volume (in mm 3 ), L equals length (in mm), and W equals width (in mm).
Statistical Analysis
All data were analyzed using SPSS 16.0 (SPSS, Inc.). The results are presented as the mean 6 standard deviation of at least three independent experiments. Comparisons between two groups were performed using Student's t tests, whereas differences in clinical characteristics were assessed using Fisher's exact test. A P value of less than .05 was considered to be statistically significant. All statistical tests were two-sided.
Results

USE1 Expression Levels in Lung Cancer Tissue
To determine the expression levels of USE1 in lung cancer, we analyzed the protein levels of USE1 in 106 paired lung cancers and their adjacent nontumoral lung tissues ( Figure 1 , A and C; Supplementary Figure 1 , available online). Strikingly, we found that USE1 were overexpressed in 92.5% of samples ( Figure 1D ) and the levels were statistically significantly upregulated in lung cancer tissues (P < .001) ( Figure 1B) . The RNA levels were also analyzed by real-time polymerase chain reaction (PCR), but no change was detected, indicating mRNA expression was not changed ( Figure  1F ). Furthermore, we performed sequencing of USE1 and found no apparent deletion or amplification, indicating no transcript variations or gene rearrangements (data not shown). Crucially, primary cells from lung cancer tissues were isolated, and the analysis confirmed the upregulated level of USE1 ( Figure 1G ).
Overexpression of USE1 in Low-Expressing Lung Cancer Cells and Its Effect on Cell Proliferation, Migration, and Invasion
To assess the effect of USE1 on lung cancer cell proliferation, we tested USE1 expression levels in different lung cancer cell lines (Supplementary Figure 2A , available online). USE1 was stably tranfected into A549 (high endogenous level of USE1) and TC1 (low endogenous level of USE1) lung cancer cell lines, respectively. Its expression was confirmed via immunoblotting ( Figure  2A ). We found that USE1 stably expressing cells displayed a statistically significant increase in cell proliferation compared with cells transfected with the vector control (P ¼ .002 and P ¼ .003, t test) ( Figure 2 , B and C; Supplementary Figure 2B , available online). In addition, using a wound-healing assay, transfected cells were revealed to have considerably increased cell migration (P < .001, t test) ( Figure 2D ). Using an invasion chamber coated with a thin layer of extracellular matrix, we further showed that overexpression of USE1 substantially increased the invasiveness of lung cancer cells, as indicated by a marked increase in the number of invaded cells (P < 0.001, t test) ( Figure  2E ). These findings were consistent with the overexpression of USE1 in lung cancer patients and suggested that overexpression of USE1 upregulates lung cancer cell proliferation, migration, and invasiveness.
Tumor Formation in Nude Mice
Having established that USE1 influences tumorigenicity in lung cancer cell lines, we addressed its role in tumor growth using subcutaneous injection of mice with control or USE1-overexpressing TC1 cells. As shown in Figure 2F , there was a ; P < .001). We also obtained similar results in a xenograft model with subcutaneous injection with control and USE1-overexpressing A549 cells (P < .001, t test) (Supplementary Figure 2E , available online).
Stable Knockdown of USE1 in High-Expressing Lung Cancer Cells and Its Effect on Cell Proliferation and Invasion
To further verify the belief that USE1 are involved in lung cancer cell proliferation and invasion, we next investigated whether inhibition of USE1 could decrease tumor cell proliferation and invasion. Using shRNA, we stably knocked down USE1 expression in both A549 and TC1 cells, respectively ( Figure 3A 
Inducible Knockdown of USE1 and Tumor Growth in a Xenograft Model
To assess the effect of USE1 on tumor formation in vivo, we transduced A549 cells with lentivirus encoding tetracyclineinducible shRNA against USE1 or GFP. Doxycycline (Dox) treatment of A549-shUSE1 cells in culture resulted in decreased USE1 protein expression compared with untreated A549-shUSE1 cells and Dox-treated A549-shGFP cells ( Figure 3E ). Next, cells stably expressing shGFP or shUSE1 were subcutaneously injected into the lower left flank of NOD-SCID mice, and doxycycline was subsequently administered daily in drinking water ( Figure 3F ) or after the average tumor size of the cohort reached approximately 75 mm 3 ( Figure 3G ) to knockdown USE1. ; P < .001) (Figure 3 , F and G). These data provide further support for the critical role of USE1 in tumor growth.
Interaction Between USE1 and APC/C
We retrovirally expressed HA-USE1 in A549 cells and performed proteomic analyses of purified HA-USE1 complexes. HA-USE1 immune complexes were purified from A549 cells with DTBP (dimethyl 3,3'-di-thiobispropionimidate) treatment, which crosslinks proteins ( Figure 4A ). The total spectral counts of each of the more than 500 unique proteins detected were processed using Comparative Proteomics Analysis Software Suite (CompPASS) to identify high-confidence candidate interaction proteins (HCIPs) ( Figure 4B ) (22, 25) . In addition to the UBA6 and UBR complex, which is usually identified in association with USE1, we also identified APC/C subunits, including both adapter proteins CDC20 and CDH1 ( Figure 4B ). To validate the physical association between CDC20 and USE1 and between CDH1 and USE1, we took advantage of antibodies that detect endogenous CDC20 and CDH1 in A549 cells. Both proteins were detected in a-USE1 immune complexes but were absent in control immune complexes ( Figure 4C ). Furthermore, we transiently coexpressed CDC20 and CDH1 with N-terminus Myc tags and USE1 with a HA tag. The a-HA immune complexes confirmed the interaction between USE1 and both CDC20 and CDH1 ( Figure 4D) .
Given that the APC/C is an essential ubiquitin ligase that targets numerous proteins for proteasomal degradation, we next tested whether USE1 can also catalyze the formation of other ubiquitin chains besides the known E2s UBCH10 and UBE2S. However, we were unable to form ubiquitin chains (data not shown). Double thymidine block experiments have previously shown that the levels of USE1 are high in the G2/M phase but low at the metaphase/anaphase transition (26) . Using nocodazole treatment, we further confirmed that USE1 are rapidly degraded during metaphase ( Figure 4F; Supplementary Figure 3 , available online).
Effects of CDH1 or CDC20 on USE1 Expression Levels
It has been established that the APC/C recognizes both KEN box and D-box motifs in substrates because mutations in these motifs in a substrate render it resistant to APC/C ubiquitination (20, 21) . Using the GPS-ARM tool (27), we identified a typical Dbox structure starting at position 164 in USE1 ( Figure 4E ). Thus, we hypothesized that USE1 might be a substrate of the APC/C and that it might be degraded through the D-box domain. Given that overexpression of either CDC20 or CDH1 alone was sufficient to induce APC-dependent degradation of normally stable substrates, we tested whether CDH1 or CDC20 promoted the degradation of USE1 in cells. HEK293T cells were cotransfected with vectors encoding HA-USE1 and increasing amounts of Myc-CDC20 or Myc-CDH1. The protein level of HA-USE1 was gradually decreased with co-expression of either CDC20 or CDH1 (Figure 4, G and I, lanes 4-7) . We also gradually increased the amount of USE1, but the protein levels CDC20 and CDH1 were unchanged (Supplementary Figure 5A , available online). In addition, the half-life of HA-USE1 was markedly decreased when it was co-expressed with CDC20 or CDH1 (Figure 4 , H and /well) and incubated for 14 days. Data are expressed 6 SD of the results obtained in three independent experiments. Two-sided Student's t test, *P < .01. C)
Overexpression of USE1 increases cell viability. Cell viability monitored over a two-day period using a CellTiter-Glo luminescent assay (n ¼ 5, with normalization to control wild-type cells at day 0). Data are expressed 6 SD of the results obtained in three independent experiments. Two-sided Student's t test, *P < .01. D) Effect of USE1 overexpression on the cell migration of TC1 cells in a wound-healing assay. Wound closure was determined in control and USE1-expressing cells at both 12-and 18-hour time points. Data are expressed 6 SD of the results obtained in three independent experiments. Two-sided Student's t test, *P < .01. Scale bar ¼ 100 lm. E) Effect of USE1 overexpression on cell invasion. Cells stably expressing USE1 were transferred into Transwell inserts containing Matrigel-coated membranes and assessed after 24-hour incubation. Data are expressed 6 SD of the results obtained in three independent experiments. Two-sided Student's t test, †P < .001. Scale bar ¼ 100 lm. F) TC1 cells stably expressing USE1 or control were subcutaneously injected into nude mice (n ¼ 10). Tumor volume was measured with digital calipers every three days after injection and calculated using the formula 0.52 Â length Â width 2 . Error bar displays SD value. P values were calculated using the two-sided Student's t test, †P < .001. USE1 ¼ UBA6-specific E2 conjugating enzyme 1. /well) and incubated for seven to 14 days. Data are expressed 6 SD of the results obtained in three independent experiments. Two-sided Student's t test, *P < .01. C)
Effect of USE1 knockdown on the cell viability of A549 human lung cancer cells. Cell viability was monitored over a four-day period using a CellTiter-Glo luminescent assay (n ¼ 5, with normalization to control wild-type cells at day 0). Data are expressed 6 SD of the results obtained in three independent experiments. Two-sided Student's t test, †P < .001. D) Effect of USE1 knockdown on cell invasion. Cells with stable knockdown of control or USE1 were transferred into Transwell inserts containing Matrigelcoated membranes and assessed after 24-hour incubation. Data are expressed 6 SD of the results obtained in three independent experiments. Two-sided Student's t test, *P < .01. Scale bar ¼ 100 lm. E) Immunoblot analysis of cells stably expressing doxycycline-inducible shGFP or shUSE1 with or without doxycycline prior to injection of the cells into mice. F and G) A549 cells stably expressing shGFP or shUSE1 were subcutaneously injected into the lower left flank of NOD-SCID mice, and tumor growth was measured at the indicated time points. Doxycycline (2 lg/mL) was administered daily or after the average tumor size of the cohort reached approximately 75 mm 3 (E) (n ¼ 7) to induce USE1 knockdown (n ¼ 7). Tumor volume was measured with digital calipers and calculated using the formula 0.52 Â length Â width 2 every three days after injection. Error bar displays SD value. P value were calculated using the two-sided Student's t test, †P < .001. USE1 ¼ UBA6-specific E2 conjugating enzyme 1. Figure 4 . Interaction between UBA6-specific E2 conjugating enzyme 1 (USE1) and anaphase-promoting complex subunits. A) Flow chart of the proteomic analysis of A549 cells stably expressing HA-USE1. B) Summary of proteomic data with total spectral counts (TSCs) and D N -scores for proteins found in association with HA-USE1. 
ARTICLE
ARTICLE Missense Mutation of USE1 in Lung Cancer Patients
Given that we found that lung cancer patient samples have higher levels of USE1 proteins, which can be degraded by the APC/C, we sequenced the lung cancer tissues analyzed in Figure  1 and Supplementary Figure 1 (available online) to identify any point mutations in USE1. We found five independent missense mutations in the D-box of USE1 at codon 164 (CGG ! CAG, CGG ! GGG) and codon 167 (CTG ! CAG, CTG ! CGG, CTG ! CCG) in 14 cancer tissue samples (13.2%) ( Figure 6C) . Notably, the Catalogue of Somatic Mutations in Cancer also confirms the presence of the R164 mutation in USE1 in lung cancer studies. Another mutation in the D-box of USE1 at codon 172 (AAT ! TAT) was found in NCI-H1793 cells. To determine whether the missense variants affect USE1 transcriptional and protein levels, we performed quantitative PCR and immunoblot analysis of primary tumors from carriers and noncarriers. We found no differences in USE1 mRNA levels in the tumor and adjacent nontumoral lung tissues ( Figure 1F ). However, we confirmed that there were statistically significant differences in USE1 protein levels using immunoblot analysis (P < .001) (Figure 1, A and B) .
Effect of APC/C on USE1-Containing Missense Mutations
We generated USE1 proteins containing the missense mutations and then examined the turnover of R164Q and R164G USE1 using cycloheximide chase experiments. Cells were cotransfected with either USE1 or mutant USE1s with CDC20, and USE1 protein levels were examined after cycloheximide addition. As expected, USE1 had a half-life of less than two hours ( Figure 6 , E and F, lanes 1-4), whereas the mutant USE1s had half-lives of more than four hours ( Figure 6, E and F, lanes 5-8) . In addition, the protein level of USE1 was gradually decreased with coexpression of CDH1, while mutant forms of USE1 protein levels were unchanged (Supplementary Figure 5 , B-E, lanes 1-3 vs lanes 4-6, and Supplementary Figure 5F , lanes 1-4 vs lanes 5-8, available online). We further determined using immunoprecipitation that mutation of the D-box of USE1 greatly reduces its association with CDH1 ( Figure 6D) . Thus, the missense mutations in the D-box of USE1 are inaccessible to the APC/C and lead to protein accumulation, which may cause cell cycle defects and eventually lead to tumor formation ( Figure 6G ).
Discussion
In our present study, we found that USE1 proteins were frequently overexpressed in human lung cancer. Furthermore, overexpression of USE1 promoted in vivo and in vitro proliferation, migration, and invasion. Conversely, knockdown of USE1 using an shRNA approach in lung cancer cells markedly reduced cell proliferation, migration, and invasion. More importantly, our in vivo xenograft mouse model also confirmed that USE1 was associated with tumor formation.
Interestingly, the use of real-time quantitative PCR of the same 106 pairs of lung cancer cases with USE1 protein overexpression showed that USE1 messenger RNA levels were similar between tumorous and nontumorous lung samples. This finding suggests that USE1 expression is post-transcriptionally deregulated in lung cancer.
The identification of the APC/C as an interacting partner of USE1 and the rapid degradation of USE1 during metaphase by our group and others (26) led us to unexpectedly identify a Dbox domain in USE1. We have presented several lines of evidence indicating that USE1 is degraded by the E3 ligases APC/ C cdh1 and APC/C cdc20 . First, overexpression of either CDH1 or CDC20 decreased the level of ectopically expressed or endogenous USE1 in a dose-dependent manner. Second, overexpression of either CDH1 or CDC20 decreased the half-life of ectopically expressed USE1 with proteasome inhibitor, preventing the degradation of USE1. Third, depletion of CDC20 led to an accumulation of endogenous USE1 protein and increased the half-life of USE1. Crucially, we sequenced the USE1 gene in the same 106 lung cancer samples and found five independent missense mutations in the D-box domain of USE1 proteins. All mutations in USE1 markedly reduced the association between USE1 and CDH1, resulting in a prolonged half-life compared with wild-type USE1. Many studies have suggested that missense mutations play substantial roles in carcinogenesis by modifying signaling Figure 6 . Effects of the anaphase-promoting complex/cyclosome on missense mutations of UBA6-specific E2 conjugating enzyme 1 (USE1). A and B) The CDH1 (4ui9 chain R)-bound USE1 (5a4p chain A) crystal structure. D-boxes are colored in yellow. The space searched for docking simulations is marked by a black square and is shown in detail in (B). C) The deduced amino acid sequences of wild-type USE1 and substituted sequences in lung cancer patients are shown in red. D) Extracts from HEK293T cells expressing mixtures of plasmids containing HA-USE1, USE1 (R164Q), USE1 (R164G), and MYC-CDH1 were immunoprecipitated with a-HA antibodies, and immune complexes were immunoblotted with the indicated antibodies. E and F) The protein half-life of missense mutated USE1 is longer than that of the wild-type USE1 protein. HEK293T cells were cotransfected with CDH1, HA-USE1, and mutant USE1 (R164G or R164Q) as indicated and then treated with cycloheximide (50 mg/mL) for the indicated time points. The cell lysates were probed with anti-MYC, -HA, and -a-tubulin antibodies. G) The proposed model by which missense mutation in USE1 proteins leads to increases in proteins that cause cell cycle defects and consequently leads to lung carcinoma. APC/C ¼ anaphase-promoting complex/cyclosome; USE1 ¼ UBA6-specific E2 conjugating enzyme 1. networks and protein-protein interactions (28) . Similarly, missense mutations in USE1 directly affected the stability of USE1 protein by altering its interaction with the APC/C and may influence critical nodes/edges in cell cycle regulation and consequently promote proliferation, migration, and invasion.
Previous studies have shown that USE1 is an E2 enzyme of another ubiquitin-like protein, FAT10, and that FAT10 plays a critical role in regulating hepatocellular carcinoma migration and invasion (29) (30) (31) . Thus, we assessed the protein and RNA levels of FAT10 in the same 106 pairs of lung cancer change cases to tissues. 106 pairs of lung cancer tissues cases. However, we did not notice any difference in protein or RNA between nontumoral tissues and lung cancer tissues (Supplementary Figure 4 , available online). Our results are consistent with previous reports that FAT10 is highly overexpressed in hepatocellular, gastrointestinal, and gynecological cancer, but not in lung cancer (30) . Hence, we believe that the FAT10-UBA6-USE1 pathway is not likely to be involved in the upregulation of USE1 in lung cancer.
Our findings have several implications for patients with lung cancer. The finding that USE1 are highly overexpressed in lung cancer patients suggests that these proteins could be used as lung cancer biomarkers. Interestingly, USE1 proteins were highly overexpressed regardless of the type or disease stage ( Figure 1E ), though we cannot rule out that our relatively small sample size may have reduced the statistical significance of the association. Additionally, our data may have therapeutic implications. We showed that doxycycline-induced USE1 knockdown led to reduced tumor formation. Notably, tumor growth was markedly delayed, even when the tumor had been formed prior to USE1 knockdown.
In summary, our study provides the first direct analysis of the role of the alternative arm of ubiquitin activation in lung cancer. We believe that, in at least some cases, missense mutations in USE1 proteins lead to substantial increases in proteins that cause cell cycle defects and consequently cause lung carcinoma.
This study also had some limitations. Because the frequency of USE1 mutations in human lung cancer is low (13.2 %), it is still unclear how USE1 contributes to tumorigenesis. Given that UBA6-USE1 also functions in the N-end rule pathway via interaction with the UBR family, additional targets downstream of UBR ligase, including RGS4 and RGS5, may also contribute to lung tumorigenesis. Interestingly, both proteins have been linked to cancer differentiation and metastasis in lung cancer (32, 33) because USE1 can interact with other RING E3 ligases and may therefore function in additional pathways that contribute to lung tumorigenesis.
To further understand the nature of the overexpression of USE1 protein, elucidation of the network, such as the substrates regulated by UBA6-USE1-E3(s) or deubiquitin enzyme(s) that regulates the USE1 stability (Supplementary Figure 6 , available online), is essential to determine the molecular mechanisms and provide additional insight into lung carcinogenesis.
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